Last reviewed · How we verify

Comparator: ibuprofen — Competitive Intelligence Brief

Comparator: ibuprofen (Comparator: ibuprofen) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Nonsteroidal anti-inflammatory drug (NSAID). Area: Pain Management, Inflammation, Rheumatology.

phase 3 Nonsteroidal anti-inflammatory drug (NSAID) COX-1, COX-2 Pain Management, Inflammation, Rheumatology Small molecule Live · refreshed every 30 min

Target snapshot

Comparator: ibuprofen (Comparator: ibuprofen) — Organon and Co. Ibuprofen inhibits cyclooxygenase (COX) enzymes to reduce prostaglandin synthesis, thereby decreasing inflammation, pain, and fever.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Comparator: ibuprofen TARGET Comparator: ibuprofen Organon and Co phase 3 Nonsteroidal anti-inflammatory drug (NSAID) COX-1, COX-2
Paracetamol + ibuprofen Paracetamol + ibuprofen Ullevaal University Hospital marketed Analgesic/antipyretic combination COX-1, COX-2 (ibuprofen); prostaglandin synthesis pathway (paracetamol)
EC Aspirin 325 EC Aspirin 325 POZEN marketed Antiplatelet agent / NSAID Cyclooxygenase (COX-1, COX-2)
naproxen sodium codein naproxen sodium codein Diskapi Yildirim Beyazit Education and Research Hospital marketed NSAID + opioid combination analgesic COX-1, COX-2, mu opioid receptor
Codeine paracetamol Codeine paracetamol Napp Pharmaceuticals Limited marketed Opioid analgesic combination Opioid receptors (μ, δ, κ); cyclooxygenase (COX-1, COX-2)
Ibuprofen 2% Ibuprofen 2% Berlin-Chemie AG Menarini Group marketed Nonsteroidal anti-inflammatory drug (NSAID) COX-1, COX-2
Non- effervescent Paracetamol kern Non- effervescent Paracetamol kern Fundacio d'Investigacio en Atencio Primaria Jordi Gol i Gurina marketed Analgesic and antipyretic Cyclooxygenase (COX-1, COX-2)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Nonsteroidal anti-inflammatory drug (NSAID) class)

  1. Università degli Studi di Brescia · 4 drugs in this class
  2. Bausch & Lomb Incorporated · 4 drugs in this class
  3. Bayer · 3 drugs in this class
  4. Pfizer · 3 drugs in this class
  5. Azienda USL Reggio Emilia - IRCCS · 3 drugs in this class
  6. Organon and Co · 3 drugs in this class
  7. Johnson & Johnson Consumer Inc., McNeil Consumer Healthcare Division · 2 drugs in this class
  8. Bezmialem Vakif University · 2 drugs in this class
  9. Guang'anmen Hospital of China Academy of Chinese Medical Sciences · 2 drugs in this class
  10. Center For Excellence In Eye Care · 2 drugs in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Comparator: ibuprofen — Competitive Intelligence Brief. https://druglandscape.com/ci/comparator-ibuprofen. Accessed 2026-05-15.

Build your own brief

Pick any drug + add comparators: